ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

KURA Kura Oncology Inc

21.76
-0.30 (-1.36%)
2024年6月8日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Kura Oncology Inc KURA NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.30 -1.36% 21.76 09:00:00
始値 安値 高値 終値 前日終値
21.72 21.26 22.29 21.76 22.06
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/6/0805:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
2024/6/0805:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/6/0805:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/6/0805:05EDGAR2Form 8-K - Current report
2024/6/0720:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
2024/5/2920:30GLOBEKura Oncology to Participate in Jefferies Global Healthcare..
2024/5/2505:06EDGAR2Form 8-K - Current report
2024/5/2107:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/5/2105:19EDGAR2Form 144 - Report of proposed sale of securities
2024/5/1420:30GLOBEKura Oncology Completes Enrollment in Registration-Directed..
2024/5/0820:30GLOBEKura Oncology to Participate in Bank of America Securities..
2024/5/0320:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
2024/5/0305:05GLOBEKura Oncology Reports First Quarter 2024 Financial Results
2024/4/2520:30GLOBEKura Oncology to Report First Quarter 2024 Financial Results
2024/4/2220:30GLOBEKura Oncology Receives Breakthrough Therapy Designation for..
2024/4/1020:30GLOBEKura Oncology to Participate in Stifel Targeted Oncology..
2024/4/0520:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
2024/3/0621:30GLOBEKura Oncology Reports First Patient Dosed in Trial of..
2024/3/0207:00GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
2024/2/2806:52EDGAR2Form S-8 - Securities to be offered to employees in employee..
2024/2/2806:03EDGAR2Form 8-K - Current report
2024/2/2806:01GLOBEKura Oncology Reports Fourth Quarter and Full Year 2023..
2024/2/2621:30GLOBEKura Oncology Doses First Patient in KOMET-008 Trial of..
2024/2/2221:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
2024/2/2021:30GLOBEKura Oncology to Report Fourth Quarter and Full Year 2023..
2024/2/1606:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2024/2/1514:15EDGAR2Form EFFECT - Notice of Effectiveness
2024/2/1507:58EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/1407:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/1007:21EDGAR2Form S-3 - Registration statement under Securities Act of..
2024/2/0221:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
2024/2/0107:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0107:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0107:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/3106:10EDGAR2Form 144 - Report of proposed sale of securities
2024/1/3021:08EDGAR2Form 8-K - Current report
2024/1/3021:00GLOBEKura Oncology Reports Positive Preliminary Ziftomenib..
2024/1/2707:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/2706:08EDGAR2Form 8-K - Current report
2024/1/2506:12EDGAR2Form 144 - Report of proposed sale of securities
2024/1/2421:00GLOBEKura Oncology Announces Oversubscribed $150 Million Private..
2024/1/0506:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0506:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0506:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0506:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0506:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0506:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2223:01EDGAR2Form 8-K - Current report
2023/12/1206:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0821:30GLOBEKura Oncology’s Menin Inhibitor Ziftomenib Selected for The..

最近閲覧した銘柄

Delayed Upgrade Clock